AURA Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.427

-17.79%

-0.433

-21.21%

-0.447

-4.96%

Estimates Revision

The market is revising No Change the revenue expectations for Aura Biosciences, Inc. (AURA) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 9.21%.

EPS Estimates for FY2025

Revise Downward

-4.79%

In Past 3 Month

Stock Price

Go Up

+9.21%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast AURA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AURA is 19.33 USD with a low forecast of 13.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 6.520

Low

13.00

Averages

19.33

High

23.00

Current: 6.520

Low

13.00

Averages

19.33

High

23.00

Evercore ISI

Outperform

initiated

$13

2025-11-25

Reason

Evercore ISI

Price Target

$13

2025-11-25

initiated

Outperform

Reason

Evercore ISI re-initiated coverage of Aura Biosciences with an Outperform rating and $13 price target. Aura uses a photosensitive payload to kill tumor cells in a handful of "underserved," early-stage indications and early data has been "quite supportive," the analyst tells investors. The company's main target populations are earlier than the market is used to considering and with a safe and easy-to-give regimen, Aura could potentially open up these indications and avoid competition, the analyst added.

H.C. Wainwright

Andres Maldonado

initiated

$22

2025-05-28

Reason

H.C. Wainwright

Andres Maldonado

Price Target

$22

2025-05-28

initiated

Reason

H.C. Wainwright analyst Andres Maldonado assumed coverage of Aura Biosciences with a Buy rating and $22 price target. Aura is advancing a tumor-targeted platform that combines localized cytotoxicity with systemic immune activation, anchored by its proprietary virus-like drug conjugate technology, the analyst tells investors in a research note. The firm says the company is positioned to redefine the treatment paradigm in ocular oncology, where early intervention is often avoided due to the destructive nature of existing therapies.

Citizens Capital Markets

Jonathan Wolleben

Buy

Maintains

$21 → $19

2025-03-26

Reason

Citizens Capital Markets

Jonathan Wolleben

Price Target

$21 → $19

2025-03-26

Maintains

Buy

Reason

HC Wainwright & Co.

Edward White

Strong Buy

Maintains

$22 → $25

2025-03-25

Reason

HC Wainwright & Co.

Edward White

Price Target

$22 → $25

2025-03-25

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Edward White

Strong Buy

Reiterates

$22

2025-03-24

Reason

HC Wainwright & Co.

Edward White

Price Target

$22

2025-03-24

Reiterates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Aura Biosciences Inc (AURA.O) is -3.74, compared to its 5-year average forward P/E of -5.47. For a more detailed relative valuation and DCF analysis to assess Aura Biosciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.47

Current PE

-3.74

Overvalued PE

-3.28

Undervalued PE

-7.66

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 593.96% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

AURA News & Events

Events Timeline

No data

News

4.0

11-27NASDAQ.COM

Evercore ISI Group Confirms Outperform Rating for Aura Biosciences (AURA)

5.0

11-21Newsfilter

NovaBridge's Visara Division Names Renowned Ophthalmology Experts as Chief Medical Officer and Chair of Scientific Advisory Board to Advance VIS-101

5.0

11-20Globenewswire

NovaBridge's Visara Division Names Renowned Ophthalmology Experts as Chief Medical Officer and Chair of Scientific Advisory Board to Advance VIS-101

People Also Watch

Frequently Asked Questions

What is Aura Biosciences Inc (AURA) stock price today?

The current price of AURA is 6.52 USD — it has decreased -0.31 % in the last trading day.

What is Aura Biosciences Inc (AURA)'s business?

Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. The Company’s lead candidate, bel-sar (AU-011), is in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. It is developing bel-sar as a potential first-line vision-sparing treatment option for early intervention in small choroidal melanoma and/or indeterminate lesions, avoiding the need for radiotherapy and reducing the risk for metastasis for these patients. Bel-sar is a virus-like drug conjugate (VDC) consisting of a human papillomavirus (HPV)-derived virus-like particle (VLP) and a phthalocyanine dye, a light-activated cytotoxic payload. The Company’s platform is designed to enable the targeting of a broad range of solid tumors using VLP, that can be conjugated with drugs or loaded with nucleic acids to create VDCs.

What is the price predicton of AURA Stock?

What is Aura Biosciences Inc (AURA)'s revenue for the last quarter?

Aura Biosciences Inc revenue for the last quarter amounts to -27.91M USD, increased 20.12 % YoY.

What is Aura Biosciences Inc (AURA)'s earnings per share (EPS) for the last quarter?

Aura Biosciences Inc. EPS for the last quarter amounts to -20189000.00 USD, increased 29.30 % YoY.

What changes have occurred in the market's expectations for Aura Biosciences Inc (AURA)'s fundamentals?

How many employees does Aura Biosciences Inc (AURA). have?

Aura Biosciences Inc (AURA) has 106 emplpoyees as of December 15 2025.

What is Aura Biosciences Inc (AURA) market cap?

Today AURA has the market capitalization of 415.31M USD.